Welcome to our dedicated page for Biovaxys Technol news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on Biovaxys Technol stock.
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biopharmaceutical company advancing novel immunotherapies through its proprietary DPX™ delivery system and HapTenix© neoantigen technology. This page provides investors and industry observers with comprehensive updates on material developments across the company's oncology and infectious disease programs.
Our curated news feed delivers timely updates on clinical trial progress, regulatory milestones, and strategic partnerships related to BioVaxys' immune-educating platforms. Users will find verified information about vaccine candidate developments, intellectual property expansions, and peer-reviewed research findings.
Key content categories include updates on DPX™-based vaccine formulations, HapTenix© neoantigen constructs, and preclinical/clinical study results. All content is sourced from official company communications and reputable financial/news outlets to ensure reliability.
Bookmark this page for streamlined access to BioVaxys' latest developments in targeted immunotherapy. Check regularly for updates on technology licensing agreements, trial phase advancements, and scientific publications demonstrating platform efficacy.
BioVaxys Technology Corp. (OTCQB: BVAXF) announced on April 17, 2023, that it has engaged Maxim Group LLC as a financial advisor and investment banker. The firm will assist with financial advisory and investment banking services, focusing on strategic planning, alliances, and US national stock exchange listing processes. BioVaxys has agreed to issue 2,902,236 common shares to Maxim, pending approval from the Canadian Securities Exchange. CEO James Passin expressed enthusiasm about working with Maxim to enhance shareholder value and explore transformative capital market opportunities. BioVaxys specializes in developing vaccines for various viruses and cancers, including a potential vaccine for Stage III/IV ovarian cancer.
BioVaxys Technology Corp. (OTCQB: BVAXF) announced the acquisition of TAETSoftware Corp, a Vancouver-based clinical studies management company. The deal involved issuing 24.5 million common shares, with an additional 2.5 million shares contingent on successful beta testing of the Trial Adverse Events Tracker (TAET) platform. This innovative application allows real-time reporting of adverse drug events in clinical trials, improving data accuracy and responsiveness. Additionally, BioVaxys completed a private placement, raising $670,000 through the issuance of 5.36 million shares. The company aims to utilize these funds for working capital and will leverage TAET to enhance revenue opportunities in the clinical study sector.
FAQ
What is the current stock price of Biovaxys Technol (BVAXF)?
What is the market cap of Biovaxys Technol (BVAXF)?
